Genzyme Defeats 1 Of 3 Defenses In Hectorol IP Suit

Law360, New York (September 20, 2010, 4:17 PM EDT) -- A federal judge has dismissed one inequitable conduct defense asserted by Cobrek Pharmaceuticals Inc. in a patent infringement suit brought by Genzyme Corp. over kidney disease treatment Hectorol, but left two other inequitable conduct defenses intact.

Biotechnology company Genzyme and a subsidiary satisfied their duty of candor with regard to eight prior art references that were material to the patentability of the asserted claims, Judge Robert M. Dow Jr. of the U.S. District Court for the Northern District of Illinois said Friday in a summary judgment...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.